On the other hand, DB08901 (Ponatinib) is a novel Bcr-Abl tyrosine kinase inhibitor that has been proven to inhibit the tyrosine kinase activity of Abl and is used to treat chronic myelogenous leukemia. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.